Kaleo
Jan 27, 2017
Payers block EpiPen; Allergan charged; AbbVie’s Humira; Baxter paying $18M
Payers block Kaléo's expensive EpiPen challenger Kaléo reintroduced its Auvi-Q last week at a list price of $4,500 for a two-pack in an effort to capture some market share from Mylan’s EpiPen, which is listed at about $600 for a two-pack. Auvi-Q is set to launch next month. Under Kaléo’s pricing strategy, Auvi-Q wil...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
